PE20020793A1 - Agente preventivo y/o terapeutico de enfermedades inflamatorias del tracto respiratorio - Google Patents

Agente preventivo y/o terapeutico de enfermedades inflamatorias del tracto respiratorio

Info

Publication number
PE20020793A1
PE20020793A1 PE2001001303A PE2001001303A PE20020793A1 PE 20020793 A1 PE20020793 A1 PE 20020793A1 PE 2001001303 A PE2001001303 A PE 2001001303A PE 2001001303 A PE2001001303 A PE 2001001303A PE 20020793 A1 PE20020793 A1 PE 20020793A1
Authority
PE
Peru
Prior art keywords
inflammatory diseases
respiratory tract
preventive
therapeutic agent
cyclopropanocarboxylate
Prior art date
Application number
PE2001001303A
Other languages
English (en)
Inventor
Teruo Komoto
Hiroyuki Mizuno
Koichi Takahashi
Yoshinori Takahashi
Susumu Sato
Original Assignee
Hisamitsu Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Medical Co Ltd filed Critical Hisamitsu Medical Co Ltd
Publication of PE20020793A1 publication Critical patent/PE20020793A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE AL USO DE DERIVADOS ESTEROIDES TAL COMO 9-FLUOR-11ß,17,21-TRIHIDROXI-16O-METIL-1,4-PREGNADIEN-3,20-DIONA; 17-CICLOPROPANOCARBOXILATO; 9-FLUOR-11ß,17,21-TRIHIDROXI-16O-METIL-1,4-PREGNADIEN-3,20-DIONA, 21-CICLOHEXANOCARBOXILATO, 17 CICLOPROPANOCARBOXILATO. LA FORMA FARMACEUTICA ES UNA COMPOSICION LIQUIDA O EN POLVO PARA INHALACION ORAL O ADMINISTRACION INTRANASAL. LOS COMPUESTOS INHIBEN LA INFLAMACION DE LOS CONDUCTOS RESPIRATORIOS Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS DEL TRACTO RESPIRATORIO TAL COMO ASMA, HIPERSENSIBILIDAD, NASAL, ALERGIA, LARINGEA, SINUSITIS
PE2001001303A 2000-12-22 2001-12-26 Agente preventivo y/o terapeutico de enfermedades inflamatorias del tracto respiratorio PE20020793A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000390941 2000-12-22

Publications (1)

Publication Number Publication Date
PE20020793A1 true PE20020793A1 (es) 2002-09-06

Family

ID=18857198

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001303A PE20020793A1 (es) 2000-12-22 2001-12-26 Agente preventivo y/o terapeutico de enfermedades inflamatorias del tracto respiratorio

Country Status (16)

Country Link
US (1) US7214672B2 (es)
EP (1) EP1344526B1 (es)
JP (1) JP3691487B2 (es)
KR (1) KR100833157B1 (es)
CN (2) CN1481246A (es)
AR (2) AR031969A1 (es)
AT (1) ATE396733T1 (es)
CA (1) CA2438799C (es)
DE (1) DE60134267D1 (es)
DK (1) DK1344526T3 (es)
ES (1) ES2305029T3 (es)
MX (1) MXPA03005660A (es)
PE (1) PE20020793A1 (es)
PT (1) PT1344526E (es)
TW (1) TWI290145B (es)
WO (1) WO2002051422A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7576001A (en) * 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
EP1383786B1 (en) * 2001-04-30 2008-10-15 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
DE60227254D1 (de) * 2001-06-12 2008-08-07 Glaxo Group Ltd Neue anti inflammatorische 17.alpha.-heterozyklische ester von 17.beta.-carbothioat androstan derivativen
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
JP3691459B2 (ja) * 2002-06-14 2005-09-07 久光メディカル株式会社 粉末状吸入剤組成物
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1645266A1 (en) * 2004-10-08 2006-04-12 Hisamitsu Medical Co., Ltd. Aqueous suspension for nasal drops
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639434A (en) * 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
SE418294B (sv) * 1974-03-27 1981-05-18 Plurichemie Anstalt Sett att framstella en 16alfa- eller 16beta-9alfa-klor eller -fluorsteroidester
US4933168A (en) * 1975-05-27 1990-06-12 Syntex Pharmaceuticals International Limited Stable, crystalline flunisolide
IL66432A0 (en) * 1981-08-04 1982-12-31 Plurichemie Anstalt Process for the preparation of steroidal esters
JPH07116215B2 (ja) * 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias

Also Published As

Publication number Publication date
DE60134267D1 (de) 2008-07-10
ATE396733T1 (de) 2008-06-15
US7214672B2 (en) 2007-05-08
EP1344526B1 (en) 2008-05-28
JP3691487B2 (ja) 2005-09-07
US20040053904A1 (en) 2004-03-18
CA2438799A1 (en) 2002-07-04
DK1344526T3 (da) 2008-09-15
MXPA03005660A (es) 2004-12-03
KR100833157B1 (ko) 2008-05-28
CA2438799C (en) 2009-09-01
WO2002051422A1 (fr) 2002-07-04
AR097737A2 (es) 2016-04-13
CN101518537A (zh) 2009-09-02
EP1344526A1 (en) 2003-09-17
EP1344526A4 (en) 2005-03-16
JPWO2002051422A1 (ja) 2004-04-22
TWI290145B (en) 2007-11-21
CN1481246A (zh) 2004-03-10
PT1344526E (pt) 2008-06-18
KR20030064414A (ko) 2003-07-31
ES2305029T3 (es) 2008-11-01
AR031969A1 (es) 2003-10-08

Similar Documents

Publication Publication Date Title
PE20020793A1 (es) Agente preventivo y/o terapeutico de enfermedades inflamatorias del tracto respiratorio
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
CO4950524A1 (es) Inhibidores de acido nitrico sintasa
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
CA2474479A1 (en) Composition for inhalation
HK1035336A1 (en) Use of preparations for the application of antiseptic agents and/or agents promoting the healing of wounds to the lower respiratory tract
CR6937A (es) Nuevo polvo inhalable conteniendo tiotropium
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
IT1255040B (it) Forma di ciclosporina adatta alla somministrazione per via polmonare eprocedimento di preparazione.
PE20081788A1 (es) Combinaciones farmaceuticas
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
AR020760A1 (es) DISPOSITIVO PARA CONTROLAR LA ADMINISTRACIoN DE UN AGENTE ACTIVO EN AEROSOL EN LOS PULMONES DE UN PACIENTE HUMANO
BR0008276A (pt) Combinações de formoterol e propionato de fluticasona para asma
AR018161A1 (es) Dispositivo para administrar un agente activo a los pulmones de un paciente humano
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
NO20044496L (no) Torr pulver innhaleringssammensetning
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
AR039409A1 (es) Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.
RU2007138263A (ru) Противовоспалительные соединения
BG107257A (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
ES2426957T3 (es) Procedimiento de tratamiento de rinosinusitis aguda
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
MX2007013466A (es) Composicion cosmetica.
AR036473A1 (es) Uso de compuestos en un inhalador de polvo seco

Legal Events

Date Code Title Description
FC Refusal